Adma Biologics reported $23.05M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Adma Biologics USD 23.05M 320K Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Dynavax Technologies USD 40.09M 1.45M Sep/2025
Takeda JPY 282.78B 29.23B Dec/2025